On September 28, 2026, Guggenheim initiated coverage of Korsana Biosciences (NASDAQCM:KRSA) with a “Buy” recommendation. The stock closed at $31.42 on this date, up from a previous close of $31.10 on September 25, marking a 1.03% increase. However, over the preceding week, the stock saw a decline of 5.39% from a high of $33.21 recorded on September 21.
This initiation follows similar actions by other firms, including Stifel and TD Cowen, both of whom also initiated coverage with a “Buy” rating on September 14, 2026. UBS had previously initiated coverage with a “Buy” on September 11, 2026, contributing to a growing positive outlook from multiple analysts within a short timeframe.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
